Short-term effects of low-dose estrogen/drospirenone vs low-dose estrogen/dydrogesterone on glycemic fluctuations in postmenopausal women with metabolic syndrome
- 7 July 2013
- journal article
- research article
- Published by Springer Nature in AGE
- Vol. 36 (1) , 265-274
Abstract
This study aims to compare the effects of low-dose emidrate estradiol/drospirenone (E2/DRSP) vs low-dose emidrate estradiol/dydrogesterone (E2/DG) combination on the mean amplitude of glycemic excursions (MAGE) value in postmenopausal women affected by metabolic syndrome (MS). One hundred sixty postmenopausal women were recruited to receive a treatment with oral doses of E2/1 mg plus drospirenone/2 mg (E2/DRSP group) or oral dose of E2/1 mg plus dydrogesterone/5 mg (E2/DG group) for 6 months. At enrollment and after 6 months, anthropometric, metabolic, and inflammatory parameters have been assessed. MAGE, evaluated during 48-h continuous subcutaneous glucose monitoring (CSGM), allowed us to assess daily glucose fluctuations at baseline and after 6 months. After hormone therapy, both groups showed a significant decline in fasting plasma glucose levels (p < 0.05), while only E2/DRSP group showed a statistically significant decline in waist circumferences, post-prandial glycemia, LDL, plasma triglycerides, MAGE, HOMA index, and plasma IL-6 (p < 0.05) levels. In the whole population (n = 160), after 6 months of indicated therapy, changes in fasting plasma glucose and PAI-1 levels correlated with the changes in MAGE values, while only in E2/DRSP group that MAGE reduction was positively associated with a stronger decrease in waist circumferences, triglycerides, and TNF-α plasma levels. The independent effect of hormone therapy (HT) on reduction in MAGE value has been tested in three different multiple linear regression models. HT resulted to be associated with MAGE, independent of other confounding variables. Although both groups had a decline in fasting plasma glucose, only drospirenone treatment revealed positive effects on glycemic excursions and insulin sensitivity, induced favorable changes in lipid profile, and showed an improvement of inflammatory indices in postmenopausal women with MS.Keywords
This publication has 38 references indexed in Scilit:
- Association of Sedentary Behaviour with Metabolic Syndrome: A Meta-AnalysisPLOS ONE, 2012
- Normal Reference Range for Mean Tissue Glucose and Glycemic Variability Derived from Continuous Glucose Monitoring for Subjects Without Diabetes in Different Ethnic GroupsDiabetes Technology & Therapeutics, 2011
- Postprandial Hyperglycemia and Glycemic VariabilityDiabetes Care, 2011
- Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot studyEuropean Journal of Endocrinology, 2009
- Effects of nonoral estradiol–micronized progesterone or low-dose oral estradiol–drospirenone therapy on metabolic variables and markers of endothelial function in early postmenopauseFertility and Sterility, 2009
- Continuous glucose monitoring in patients with type 2 diabetes: Why? When? Whom?Diabetes & Metabolism, 2007
- Effects of a New Hormone Therapy, Drospirenone and 17-β-Estradiol, in Postmenopausal Women With HypertensionHypertension, 2006
- Progestogens of varying androgenicity and cardiovascular risk factors in postmenopausal women receiving oestrogen replacement therapyClinical Endocrinology, 2004
- Glucose and Insulin Components of the Metabolic Syndrome Are Associated with Hyperandrogenism in Postmenopausal Women: The Atherosclerosis Risk in Communities StudyAmerican Journal of Epidemiology, 2004
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002